-
1دورية أكاديمية
المؤلفون: Lonnerholm, G, Frost, BM, Abrahamsson, J, Behrendtz, M, Castor, A, Forestier, E, Heyman, M, Uges, DRA, de Graaf, SSN
المصدر: British journal of haematology. 142(4):616-621
مصطلحات موضوعية: Medicin och hälsovetenskap
-
2دورية أكاديمية
المؤلفون: Maring, JG, van Kuilenburg, ABP, Haasjes, J, Piersma, H, Groen, HJM, Uges, DRA, Van Gennip, AH, De Vries, EGE
المصدر: Maring , JG , van Kuilenburg , ABP , Haasjes , J , Piersma , H , Groen , HJM , Uges , DRA , Van Gennip , AH & De Vries , EGE 2002 , ' Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene ' , British Jounal of Cancer , vol. 86 , no. 7 , pp. 1028-1033 . https://doi.org/10.1038/sj/bjc/6600208Test
مصطلحات موضوعية: DPD, 5-fluorouracil, pharmacokinetics, DPYD gene, mutation, pharmacogenetics, DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY, CANCER-PATIENTS, 5-FLUOROURACIL CHEMOTHERAPY, POPULATION CHARACTERISTICS, MONONUCLEAR-CELLS, DEFICIENCY, TOXICITY, PLASMA, FLUOROURACIL
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1038/sj/bjc/6600208Test
https://hdl.handle.net/11370/fede70af-4425-4b7b-b1d1-22e5a79955acTest
https://research.rug.nl/en/publications/fede70af-4425-4b7b-b1d1-22e5a79955acTest
https://pure.rug.nl/ws/files/62260297/Reduced_5_FU_clearance_in_a_patient_with_low_DPD_activity.pdfTest -
3دورية أكاديمية
المؤلفون: Paridaens, R, Uges, DRA, Barbet, N, Choi, L, Seeghers, M, van der Graaf, WTA, Groen, HJM, Dumez, H, Van Buuren, I, Muskiet, F, Capdeville, R, van Oosterom, AT, de Vries, EGE
المصدر: Paridaens , R , Uges , DRA , Barbet , N , Choi , L , Seeghers , M , van der Graaf , WTA , Groen , HJM , Dumez , H , Van Buuren , I , Muskiet , F , Capdeville , R , van Oosterom , AT & de Vries , EGE 2000 , ' A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours ' , British Jounal of Cancer , vol. 83 , no. 5 , pp. 594-601 . https://doi.org/10.1054/bjoc.2000.1305Test
مصطلحات موضوعية: polyamine, SAMDC, phase I, 5FU, neutropenia, S-ADENOSYLMETHIONINE DECARBOXYLASE, ENZYME TARGET, CHROMATOGRAPHY, THERAPY, GROWTH
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1054/bjoc.2000.1305Test
https://hdl.handle.net/11370/a9f5b412-43ff-49d8-99fd-f56846fe9283Test
https://research.rug.nl/en/publications/a9f5b412-43ff-49d8-99fd-f56846fe9283Test
https://pure.rug.nl/ws/files/62261558/A_phase_I_study_of_a_new_polyamine_biosynthesis_inhibitor.pdfTest -
4دورية أكاديمية
المؤلفون: Fokkema, E, Verweij, J, van Oosterom, AT, Uges, DRA, Spinelli, R, Valota, O, de Vries, EGE, Green, HJM
المصدر: Fokkema , E , Verweij , J , van Oosterom , AT , Uges , DRA , Spinelli , R , Valota , O , de Vries , EGE & Green , HJM 2000 , ' A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours : a phase 1 and pharmacokinetic study ' , British Jounal of Cancer , vol. 82 , no. 4 , pp. 767-771 . https://doi.org/10.1054/bjoc.1999.0996Test
مصطلحات موضوعية: methoxymorpholino doxorubicin, pharmacokinetics, phase I study, CELL LUNG-CANCER, CONTINUOUS INTRAVENOUS-INFUSION, TOPOISOMERASE-II ACTIVITY, MORPHOLINYL ANTHRACYCLINES, BREAST-CANCER, RESISTANT, PHARMACOLOGY, FCE-23762, LINES
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1054/bjoc.1999.0996Test
https://hdl.handle.net/11370/93c5e0cd-52c3-497f-87a4-6f0709165b92Test
https://research.rug.nl/en/publications/93c5e0cd-52c3-497f-87a4-6f0709165b92Test
https://pure.rug.nl/ws/files/62263967/A_prolonged_methoxymorpholino_doxorubicin.pdfTest -
5دورية أكاديمية
المؤلفون: de Jong, RS, Mulder, NH, Uges, DRA, Sleijfer, DT, Hoppener, FJP, Groen, HJM, Willemse, PHB, van der Graaf, WTA, de Vries, EGE
المصدر: de Jong , RS , Mulder , NH , Uges , DRA , Sleijfer , DT , Hoppener , FJP , Groen , HJM , Willemse , PHB , van der Graaf , WTA & de Vries , EGE 1999 , ' Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin ' , British Jounal of Cancer , vol. 79 , no. 5-6 , pp. 882-887 . https://doi.org/10.1038/sj.bjc.6690141Test
مصطلحات موضوعية: fostriecin, topoisomerase II, phase I, pharmacokinetics, CARCINOMA CELL-LINE, ANTIBIOTIC CL-920, RESISTANCE, ASSAY
وصف الملف: application/pdf
الإتاحة: https://doi.org/10.1038/sj.bjc.6690141Test
https://hdl.handle.net/11370/cbf9ea2f-55f8-40a2-87e0-48d62ac35150Test
https://research.rug.nl/en/publications/cbf9ea2f-55f8-40a2-87e0-48d62ac35150Test
https://pure.rug.nl/ws/files/62265499/Phase_I_and_pharmacokinetic_study_of_the.pdfTest -
6دورية أكاديمية
المؤلفون: Hettinga, JVE, Lemstra, W, Meijer, C, Dam, WA, Uges, DRA, Konings, AWT, De Vries, EGE, Kampinga, HH
المصدر: British Journal of Cancer ; volume 75, issue 12, page 1735-1743 ; ISSN 0007-0920 1532-1827
مصطلحات موضوعية: Cancer Research, Oncology
الإتاحة: https://doi.org/10.1038/bjc.1997.297Test
http://www.nature.com/articles/bjc1997297.pdfTest
http://www.nature.com/articles/bjc1997297Test -
7دورية أكاديمية
المؤلفون: de Jong, RS, Mulder, NH, Uges, DRA, Kaul, S, Winograd, B, Sleijfer, DTh, Groen, HJM, Willemse, PHB, van der Graaf, WTA, de Vries, EGE
المصدر: British Journal of Cancer ; volume 75, issue 11, page 1660-1666 ; ISSN 0007-0920 1532-1827
مصطلحات موضوعية: Cancer Research, Oncology
الإتاحة: https://doi.org/10.1038/bjc.1997.282Test
http://www.nature.com/articles/bjc1997282.pdfTest
http://www.nature.com/articles/bjc1997282Test -
8دورية أكاديمية
المؤلفون: Groen, HJM, van der Leest, AHD, de Vries, EGE, Uges, DRA, Szabó, BG, Mulder, NH
المصدر: British Journal of Cancer ; volume 72, issue 4, page 992-997 ; ISSN 0007-0920 1532-1827
مصطلحات موضوعية: Cancer Research, Oncology
الإتاحة: https://doi.org/10.1038/bjc.1995.448Test
http://www.nature.com/articles/bjc1995448.pdfTest
http://www.nature.com/articles/bjc1995448Test -
9دورية أكاديمية
المؤلفون: Guchelaar, H-J, Hoekstra, HJ, de Vries, EGE, Uges, DRA, Oosterhuis, JW, Schraffordt Koops, H
المصدر: British Journal of Cancer ; volume 65, issue 6, page 898-902 ; ISSN 0007-0920 1532-1827
مصطلحات موضوعية: Cancer Research, Oncology
الإتاحة: https://doi.org/10.1038/bjc.1992.188Test
http://www.nature.com/articles/bjc1992188.pdfTest
http://www.nature.com/articles/bjc1992188Test -
10
المؤلفون: Gietema, JA, Hoekstra, R (Rosa), de Vos, FYFL, de Vries, EGE, Uges, DRA, van der Gaast, Ate, Groen, HJM, Loos, Walter, Knight, RA, Karyekar, CS, Daskowski, D, McKeegan, E, Knight, R, Humerickhouse, R, Verweij, Jaap, Eskens, Ferry
المساهمون: Groningen Research Institute of Pharmacy, Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical Oncology
المصدر: Annals of Oncology, 17(8), 1320-1327. Oxford University Press
Annals of Oncology, 17, 1320-1327. Elsevier Ltd.مصطلحات موضوعية: Adult, Male, Bevacizumab, CELL LUNG-CANCER, medicine.medical_treatment, BEVACIZUMAB, cisplatin, Angiogenesis Inhibitors, PACLITAXEL, Pharmacology, Deoxycytidine, LEUCOVORIN, Thrombospondin 1, Pharmacokinetics, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Drug Interactions, Aged, Cisplatin, Chemotherapy, business.industry, gemcitabine, ABT-510, Hematology, Middle Aged, phase I, Chemotherapy regimen, RANDOMIZED-TRIAL, FLUOROURACIL, Gemcitabine, SU5416, METASTATIC COLORECTAL-CANCER, angiogenesis inhibitor, Oncology, Fluorouracil, Female, business, Oligopeptides, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d734c24e74dad1fadaf87c42dad5b107Test
https://doi.org/10.1093/annonc/mdl102Test